Testing effectiveness (Phase 2)UnknownNCT04935580What this trial is testingStudy of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsWho this might be right forMultiple Myeloma Shanghai Changzheng Hospital 20
Testing effectiveness (Phase 2)UnknownNCT03809780What this trial is testingStudy to Demonstrate Clinical Benefit of Lenalidomide and DexamethasoneWho this might be right forMultiple Myeloma Kosin University Gospel Hospital 70
Testing effectiveness (Phase 2)Study completedNCT00024466What this trial is testingChemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 28
Not applicableLooking for participantsNCT05259553What this trial is testingBiomarkers in Multiple MyelomaWho this might be right forHematological PatientsNewly Diagnosed Multiple MyelomaChemotherapy Centre Hospitalier Universitaire de Saint Etienne 70
Testing effectiveness (Phase 2)Study completedNCT00410657What this trial is testingAlemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantWho this might be right forBreast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more Fred Hutchinson Cancer Center 53
Testing effectiveness (Phase 2)Looking for participantsNCT05572229What this trial is testingStudy of Teclistamab in Combination in Elderly Patients With Multiple MyelomaWho this might be right forMultiple Myeloma University Hospital, Lille 74
Testing effectiveness (Phase 2)WithdrawnNCT03608501What this trial is testingIxazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationWho this might be right forMultiple Myeloma Takeda
Testing effectiveness (Phase 2)UnknownNCT00378755What this trial is testingSequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMMWho this might be right forMultiple Myeloma Korean Multiple Myeloma Working Party 62
Testing effectiveness (Phase 2)Study completedNCT01718743What this trial is testingIxazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWho this might be right forHematopoietic Cell Transplantation RecipientPlasma Cell Myeloma M.D. Anderson Cancer Center 64
Very early researchLooking for participantsNCT06407947What this trial is testingStudy of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma Shanghai Changzheng Hospital 10
Large-scale testing (Phase 3)Study completedNCT00950768What this trial is testingMelphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma PatientsWho this might be right forMultiple MyelomaDiagnosis Azienda Ospedaliera San Giovanni Battista 298
Not applicableStudy completedNCT03006315What this trial is testingMobile Health Device Study for Myeloma PatientsWho this might be right forMultiple MyelomaMyeloma Memorial Sloan Kettering Cancer Center 40
Large-scale testing (Phase 3)Study completedNCT00097981What this trial is testingThalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 225
Early research (Phase 1)Ended earlyNCT04892264What this trial is testingBelantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaWho this might be right forPlasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Mayo Clinic 5
Post-approval studies (Phase 4)Ended earlyNCT02773550What this trial is testingTreatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Basque Health Service 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06799676What this trial is testingA Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaWho this might be right forNewly Diagnosed Multiple Myeloma Fuling Zhou 42
Early research (Phase 1)Not Yet RecruitingNCT07114432What this trial is testingRN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple MyelomaWho this might be right forNewly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM) Tianjin Medical University Cancer Institute and Hospital 19
Not applicableStudy completedNCT01132833What this trial is testingBiomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving ChemotherapyWho this might be right forMultiple MyelomaPlasma Cell NeoplasmThromboembolism UNC Lineberger Comprehensive Cancer Center 18
Not applicableLooking for participantsNCT06497738What this trial is testingA Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma The First Affiliated Hospital with Nanjing Medical University 112
Not applicableUnknownNCT05218603What this trial is testingEvaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTWho this might be right forMultiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT) PETHEMA Foundation 100